Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(6):917–923. doi: 10.1054/bjoc.2001.1993

Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice

M Di Benedetto 1, Y Kourbali 1, A Starzec 2, R Vassy 2, J Jozefonvicz 3, G Perret 2, M Crepin 1, M Kraemer 1
PMCID: PMC2375080  PMID: 11556846

Abstract

Sodium phenylacetate (NaPa) and carboxymethyl benzylamide dextran derivative (CMDBLS4) are able to inhibit growth of breast tumour cells. In this study, we explored whether the combination of NaPa and CMDBLS4 may enhance their respective inhibitory effects on the MCF-7ras cell growth in vitro and in vivo. NaPa inhibited MCF-7ras cell proliferation by reducing the DNA replication concomitantly with a recruitment of cells in G0/G1 phase and by inducing apoptosis in a dose- and time-dependent manner. The addition of CMDBLS4 potentiated the NaPa antiproliferative effect in the manner dependent on the ratio of CMDBLS4 and NaPa concentrations. In nude mice, CMDBLS4 (150 mg kg−1) or NaPa (40 mg kg−1) administrated twice a week, for 7 weeks inhibited MCF-7ras xenograft growth by 40% and 60%, respectively. The treatment by both, CMDBLS4 and NaPa, decreased tumour growth by 83% without any toxicity. To better understand the mechanism of NaPa and CMDBLS4 action we assessed their effect on mitogenic activity of MCF-7ras conditioned medium (CM) on BALBC/3T3 fibroblasts. CMDBLS4 added to the CM, inhibited its mitogenic activity whereas NaPa had an anti-mitogenic effect when CM was prepared from MCF-7ras cells pretreated with NaPa. Thus, the antiproliferative effects of NaPa and CMDBLS4 involve 2 different mechanisms explaining, at least in part, the possible synergism between them. Overall, this study points to the potential use of a combination of dextran derivatives with NaPa to inhibit the breast tumour growth. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: sodium phenylacetate (NaPa), carboxymethyl benzylamide dextran derivative (CMDB), synergism, MCF-7ras, breast cancer

Full Text

The Full Text of this article is available as a PDF (426.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam L., Crépin M., Isräel L. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res. 1997 Mar 15;57(6):1023–1029. [PubMed] [Google Scholar]
  2. Adam L., Crépin M., Savin C., Israël L. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res. 1995 Nov 15;55(22):5156–5160. [PubMed] [Google Scholar]
  3. Albini A., Graf J., Kitten G. T., Kleinman H. K., Martin G. R., Veillette A., Lippman M. E. 17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8182–8186. doi: 10.1073/pnas.83.21.8182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bagheri-Yarmand R., Kourbali Y., Mabilat C., Morère J. F., Martin A., Lu H., Soria C., Jozefonvicz J., Crépin M. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer. 1998 Jul;78(1):111–118. doi: 10.1038/bjc.1998.451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bagheri-Yarmand R., Kourbali Y., Morère J. F., Jozefonvicz J., Crépin M. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor beta1 and platelet-derived growth factor-BB. Cell Growth Differ. 1998 Jun;9(6):497–504. [PubMed] [Google Scholar]
  6. Bagheri-Yarmand R., Kourbali Y., Rath A. M., Vassy R., Martin A., Jozefonvicz J., Soria C., Lu H., Crépin M. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. Cancer Res. 1999 Feb 1;59(3):507–510. [PubMed] [Google Scholar]
  7. Bagheri-Yarmand R., Liu J. F., Ledoux D., Morère J. F., Crépin M. Inhibition of human breast epithelial HBL100 cell proliferation by a dextran derivative (CMDB7): interference with the FGF2 autocrine loop [corrected]. Biochem Biophys Res Commun. 1997 Oct 20;239(2):424–428. doi: 10.1006/bbrc.1997.7483. [DOI] [PubMed] [Google Scholar]
  8. Bagheri-Yarmand R., Morere J. F., Letourneur D., Jozefonvicz J., Israel L., Crepin M. Inhibitory effects of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res. 1992 Sep-Oct;12(5):1641–1646. [PubMed] [Google Scholar]
  9. Berenbaum M. C. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981;35:269–335. doi: 10.1016/s0065-230x(08)60912-4. [DOI] [PubMed] [Google Scholar]
  10. Bronzert D. A., Pantazis P., Antoniades H. N., Kasid A., Davidson N., Dickson R. B., Lippman M. E. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5763–5767. doi: 10.1073/pnas.84.16.5763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chang S. M., Kuhn J. G., Robins H. I., Schold S. C., Spence A. M., Berger M. S., Mehta M. P., Bozik M. E., Pollack I., Schiff D. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol. 1999 Mar;17(3):984–990. doi: 10.1200/JCO.1999.17.3.984. [DOI] [PubMed] [Google Scholar]
  12. Dickson R. B., Kasid A., Huff K. K., Bates S. E., Knabbe C., Bronzert D., Gelmann E. P., Lippman M. E. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A. 1987 Feb;84(3):837–841. doi: 10.1073/pnas.84.3.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ferrandina G., Melichar B., Loercher A., Verschraegen C. F., Kudelka A. P., Edwards C. L., Scambia G., Kavanagh J. J., Abbruzzese J. L., Freedman R. S. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res. 1997 Oct 1;57(19):4309–4315. [PubMed] [Google Scholar]
  14. Formigli L., Papucci L., Tani A., Schiavone N., Tempestini A., Orlandini G. E., Capaccioli S., Orlandini S. Z. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol. 2000 Jan;182(1):41–49. doi: 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  15. Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987 Feb 13;48(3):417–428. doi: 10.1016/0092-8674(87)90193-0. [DOI] [PubMed] [Google Scholar]
  16. Mauzac M., Jozefonvicz J. Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization. Biomaterials. 1984 Sep;5(5):301–304. doi: 10.1016/0142-9612(84)90078-4. [DOI] [PubMed] [Google Scholar]
  17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  18. Samid D., Hudgins W. R., Shack S., Liu L., Prasanna P., Myers C. E. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol. 1997;400A:501–505. doi: 10.1007/978-1-4615-5325-0_67. [DOI] [PubMed] [Google Scholar]
  19. Samid D., Shack S., Myers C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 1993 May;91(5):2288–2295. doi: 10.1172/JCI116457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Samid D., Wells M., Greene M. E., Shen W., Palmer C. N., Thibault A. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res. 2000 Mar;6(3):933–941. [PubMed] [Google Scholar]
  21. Shack S., Miller A., Liu L., Prasanna P., Thibault A., Samid D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin Cancer Res. 1996 May;2(5):865–872. [PubMed] [Google Scholar]
  22. Sommers C. L., Papageorge A., Wilding G., Gelmann E. P. Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of rasH. Cancer Res. 1990 Jan 1;50(1):67–71. [PubMed] [Google Scholar]
  23. Spandidos D. A., Agnantis N. J. Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res. 1984 Jul-Oct;4(4-5):269–272. [PubMed] [Google Scholar]
  24. Thibault A., Cooper M. R., Figg W. D., Venzon D. J., Sartor A. O., Tompkins A. C., Weinberger M. S., Headlee D. J., McCall N. A., Samid D. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 1994 Apr 1;54(7):1690–1694. [PubMed] [Google Scholar]
  25. Thibout D., Di Benedetto M., Kraemer M., Sainte-Catherine O., Derbin C., Crépin M. Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines. Anticancer Res. 1998 Jul-Aug;18(4A):2657–2661. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES